TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 1nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 1.40nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 2.30nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 4.80nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 5.90nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 6.20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 6.5nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 7.40nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 7.80nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 9.40nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 9.5nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 10nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 11nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 12nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 12nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 13nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 18nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 21nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 22nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 22nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 28nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 30nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 35nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 36nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 44nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 45nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 46nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 49nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 52nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 69nMpH: 7.6 T: 2°CAssay Description:A typical PDE2A assay was performed as follows: the assay was performed in 60 μL samples containing a fixed amount of the PDE2A enzyme (sufficie...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 73nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 74nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 91nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 120nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 130nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 190nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 330nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 350nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 471nMpH: 7.6 T: 2°CAssay Description:A typical PDE2A assay was performed as follows: the assay was performed in 60 μL samples containing a fixed amount of the PDE2A enzyme (sufficie...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 504nMpH: 7.6 T: 2°CAssay Description:A typical PDE2A assay was performed as follows: the assay was performed in 60 μL samples containing a fixed amount of the PDE2A enzyme (sufficie...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 800nMpH: 7.5 T: 2°CAssay Description:Enzymatic activities were assayed using [3H] cAMP and [3H]cGMP as substrate.More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 2.16E+3nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 3.30E+3nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: >4.00E+3nMpH: 7.5Assay Description:The test substances are dissolved in 100% DMSO and serially diluted to determine their in vitro effect on PDE 9A. Typically, serial dilutions from 20...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: >4.00E+3nMpH: 7.5Assay Description:The test substances are dissolved in 100% DMSO and serially diluted to determine their in vitro effect on PDE 9A. 2 uL portions of the diluted substa...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 7.38E+3nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 1.00E+4nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies
US Patent
Intra-Cellular Therapies
US Patent
Affinity DataIC50: 1.00E+4nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair